Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Vaccine|September 24, 2009
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adultsWendy A Keitel, Cornelia L Dekker, ChrisAnna Mink, et al.
The Journal of Infectious Diseases|February 2, 2011
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variantRobert B Belshe, Sharon E Frey, Irene Graham, et al.
Vaccine|July 7, 2009
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adultsRebecca C Brady, John J Treanor, Robert L Atmar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2018
A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS IIISharon L Hillier, Patricia Ferrieri, Morven S Edwards, et al.
Vaccines|February 12, 2020
Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara VaccineEvan J Anderson, Lilin Lai, Jens Wrammert, et al.
Journal of the Pediatric Infectious Diseases Society|September 4, 2015
Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of AgeNatasha B Halasa, Michael A Gerber, Andrea A Berry, et al.
The Journal of Infectious Diseases|February 26, 2015
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) VaccinePatricia L Winokur, Shital M Patel, Rebecca Brady, et al.
JAMA|October 8, 2014
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trialMark J Mulligan, David I Bernstein, Patricia Winokur, et al.
The Journal of Infectious Diseases|March 6, 2021
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity ResponsesSharon E Frey, Jack T Stapleton, Zuhair K Ballas, et al.
Vaccines|March 19, 2020
Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 VaccineLilin Lai, Nadine Rouphael, Yongxian Xu, et al.
Pageof 7